1
Country: USA | Funding: $440.1M
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
2
Country: China | Funding: $308M
Rapport Therapeutics develops drugs for the treatment of central nervous system disorders. Its lead asset RAP-219 is designed for the treatment of focal epileptic seizures and primary generalized tonic-clonic seizures. It's a potential first-in-class negative allosteric modulator of the AMPA receptor, specific for TARPγ8. RAP-219 has multiple indications, including focal epilepsy and acute mania in bipolar disorder, as well as an anticonvulsant. The company has secured development and commercialization rights for its lead drug in Greater China.
Rapport Therapeutics develops drugs for the treatment of central nervous system disorders. Its lead asset RAP-219 is designed for the treatment of focal epileptic seizures and primary generalized tonic-clonic seizures. It's a potential first-in-class negative allosteric modulator of the AMPA receptor, specific for TARPγ8. RAP-219 has multiple indications, including focal epilepsy and acute mania in bipolar disorder, as well as an anticonvulsant. The company has secured development and commercialization rights for its lead drug in Greater China.
3
Country: UK | Funding: $1.2B
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
GW has established a world leading position in the development of plant-derived cannabinoid therapeutics through its proven drug discovery and development processes, intellectual property portfolio and regulatory and manufacturing expertise.
4
Country: USA | Funding: $573.1M
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
5
Country: USA | Funding: $457.1M
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
6
Country: USA | Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
7
Country: USA | Funding: $135.5M
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
8
Country: USA | Funding: $54.4M
Zeto is transforming EEG for hospitals with a wireless, zero-prep, dry electrode headset backed by a state-of-the-art cloud platform
Zeto is transforming EEG for hospitals with a wireless, zero-prep, dry electrode headset backed by a state-of-the-art cloud platform
9
Country: Italy | Funding: $35.6M
We design and develop the world's smallest and most accurate wearable devices for medical research and epilepsy management.
We design and develop the world's smallest and most accurate wearable devices for medical research and epilepsy management.
10
Country: Australia | Funding: AUD$34M
Seer is a medical technology company that specializes in addressing neurological conditions. It created at-home electroencephalograph (EEG) system, Seer Home, which helps providers diagnose epilepsy.
Seer is a medical technology company that specializes in addressing neurological conditions. It created at-home electroencephalograph (EEG) system, Seer Home, which helps providers diagnose epilepsy.
11
Country: USA | Funding: $18.4M
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
12
Country: Netherlands
LivAssured develops NightWatch - the armband that notifies caregivers remotely of nightly epileptic seizures.
LivAssured develops NightWatch - the armband that notifies caregivers remotely of nightly epileptic seizures.
13
Country: India
TerraBlue XT develops epilepsy-glove that predicts the onset of epilepsy so that patients could be provided with an early intervention, helps doctors make data-driven decisions, instead of assumption-driven ones, enabling them to check the efficacy of medications.
TerraBlue XT develops epilepsy-glove that predicts the onset of epilepsy so that patients could be provided with an early intervention, helps doctors make data-driven decisions, instead of assumption-driven ones, enabling them to check the efficacy of medications.
